Teligent (TLGT) & Aquinox Pharmaceuticals (NASDAQ:AQXP) Financial Contrast

Teligent (NASDAQ: TLGT) and Aquinox Pharmaceuticals (NASDAQ:AQXP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, profitabiliy and risk.

Profitability

This table compares Teligent and Aquinox Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Teligent	-14.35%	5.43%	1.74%
Aquinox Pharmaceuticals	N/A	-29.19%	-27.46%

Volatility and Risk

Teligent has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Comparatively, Aquinox Pharmaceuticals has a beta of -17.03, indicating that its share price is 1,803% less volatile than the S&P 500.

Institutional and Insider Ownership

62.8% of Teligent shares are held by institutional investors. Comparatively, 98.3% of Aquinox Pharmaceuticals shares are held by institutional investors. 22.6% of Teligent shares are held by insiders. Comparatively, 2.7% of Aquinox Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Teligent and Aquinox Pharmaceuticals’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	EBITDA	Earnings Per Share	Price/Earnings Ratio
Teligent	$71.12 million	5.31	$9.15 million	($0.19)	-37.32
Aquinox Pharmaceuticals	N/A	N/A	N/A	($1.93)	-7.73

Teligent has higher revenue and earnings than Aquinox Pharmaceuticals. Teligent is trading at a lower price-to-earnings ratio than Aquinox Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Teligent and Aquinox Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teligent	0	1	2	0	2.67
Aquinox Pharmaceuticals	0	1	4	0	2.80

Teligent presently has a consensus price target of $10.00, suggesting a potential upside of 41.04%. Aquinox Pharmaceuticals has a consensus price target of $20.75, suggesting a potential upside of 39.08%. Given Teligent’s higher possible upside, equities research analysts clearly believe Teligent is more favorable than Aquinox Pharmaceuticals.

Summary

Teligent beats Aquinox Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Teligent

Teligent, Inc. is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 34 Abbreviated New Drug Application(ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2016.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. Its product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. AQX-1125 is a SHIP1 activator that has demonstrated preliminary safety, anti-inflammatory potential and drug properties in multiple preclinical studies.